258 related articles for article (PubMed ID: 20518856)
1. The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat.
McKernan DP; Fitzgerald P; Dinan TG; Cryan JF
Neurogastroenterol Motil; 2010 Sep; 22(9):1029-35, e268. PubMed ID: 20518856
[TBL] [Abstract][Full Text] [Related]
2. Colorectal distension-induced prefrontal cortex activation in the Wistar-Kyoto rat: implications for irritable bowel syndrome.
Gibney SM; Gosselin RD; Dinan TG; Cryan JF
Neuroscience; 2010 Feb; 165(3):675-83. PubMed ID: 19765638
[TBL] [Abstract][Full Text] [Related]
3. Bifidobacterium infantis 35624: a novel probiotic for the treatment of irritable bowel syndrome.
Brenner DM; Chey WD
Rev Gastroenterol Disord; 2009; 9(1):7-15. PubMed ID: 19367213
[TBL] [Abstract][Full Text] [Related]
4. 5-HT(2B) receptors modulate visceral hypersensitivity in a stress-sensitive animal model of brain-gut axis dysfunction.
O'Mahony SM; Bulmer DC; Coelho AM; Fitzgerald P; Bongiovanni C; Lee K; Winchester W; Dinan TG; Cryan JF
Neurogastroenterol Motil; 2010 May; 22(5):573-8, e124. PubMed ID: 20003079
[TBL] [Abstract][Full Text] [Related]
5. Review article: probiotics and prebiotics in irritable bowel syndrome.
Spiller R
Aliment Pharmacol Ther; 2008 Aug; 28(4):385-96. PubMed ID: 18532993
[TBL] [Abstract][Full Text] [Related]
6. A marketed fermented dairy product containing Bifidobacterium lactis CNCM I-2494 suppresses gut hypersensitivity and colonic barrier disruption induced by acute stress in rats.
Agostini S; Goubern M; Tondereau V; Salvador-Cartier C; Bezirard V; Lévèque M; Keränen H; Theodorou V; Bourdu-Naturel S; Goupil-Feuillerat N; Legrain-Raspaud S; Eutamene H
Neurogastroenterol Motil; 2012 Apr; 24(4):376-e172. PubMed ID: 22272920
[TBL] [Abstract][Full Text] [Related]
7. Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.
Desbonnet L; Garrett L; Clarke G; Kiely B; Cryan JF; Dinan TG
Neuroscience; 2010 Nov; 170(4):1179-88. PubMed ID: 20696216
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome.
Whorwell PJ; Altringer L; Morel J; Bond Y; Charbonneau D; O'Mahony L; Kiely B; Shanahan F; Quigley EM
Am J Gastroenterol; 2006 Jul; 101(7):1581-90. PubMed ID: 16863564
[TBL] [Abstract][Full Text] [Related]
9. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome.
Drouault-Holowacz S; Bieuvelet S; Burckel A; Cazaubiel M; Dray X; Marteau P
Gastroenterol Clin Biol; 2008 Feb; 32(2):147-52. PubMed ID: 18387426
[TBL] [Abstract][Full Text] [Related]
10. Clinical studies on alleviating the symptoms of irritable bowel syndrome.
Kajander K; Korpela R
Asia Pac J Clin Nutr; 2006; 15(4):576-80. PubMed ID: 17077079
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis.
Yuan F; Ni H; Asche CV; Kim M; Walayat S; Ren J
Curr Med Res Opin; 2017 Jul; 33(7):1191-1197. PubMed ID: 28166427
[TBL] [Abstract][Full Text] [Related]
12. Probiotics and irritable bowel syndrome: rationale, mechanisms, and efficacy.
Camilleri M
J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 1():S123-5. PubMed ID: 18806702
[TBL] [Abstract][Full Text] [Related]
13. [Probiotic therapy of the irritable bowel syndrome].
Enck P; Klosterhalfen S; Martens U
Dtsch Med Wochenschr; 2011 Feb; 136(8):371-5. PubMed ID: 21332036
[TBL] [Abstract][Full Text] [Related]
14. The probiotic Bifidobacteria infantis: An assessment of potential antidepressant properties in the rat.
Desbonnet L; Garrett L; Clarke G; Bienenstock J; Dinan TG
J Psychiatr Res; 2008 Dec; 43(2):164-74. PubMed ID: 18456279
[TBL] [Abstract][Full Text] [Related]
15. Effect of a symbiotic preparation on the clinical manifestations of irritable bowel syndrome, constipation-variant. Results of an open, uncontrolled multicenter study.
Colecchia A; Vestito A; La Rocca A; Pasqui F; Nikiforaki A; Festi D;
Minerva Gastroenterol Dietol; 2006 Dec; 52(4):349-58. PubMed ID: 17108864
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study.
Williams EA; Stimpson J; Wang D; Plummer S; Garaiova I; Barker ME; Corfe BM
Aliment Pharmacol Ther; 2009 Jan; 29(1):97-103. PubMed ID: 18785988
[TBL] [Abstract][Full Text] [Related]
17. Probiotics and irritable bowel syndrome: rationale and clinical evidence for their use.
Barbara G; Stanghellini V; Cremon C; De Giorgio R; Gargano L; Cogliandro R; Pallotti F; Corinaldesi R
J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 2():S214-7. PubMed ID: 18685517
[TBL] [Abstract][Full Text] [Related]
18. Repeated electro-acupuncture attenuates chronic visceral hypersensitivity and spinal cord NMDA receptor phosphorylation in a rat irritable bowel syndrome model.
Tian SL; Wang XY; Ding GH
Life Sci; 2008 Aug; 83(9-10):356-63. PubMed ID: 18694764
[TBL] [Abstract][Full Text] [Related]
19. Differential visceral nociceptive, behavioural and neurochemical responses to an immune challenge in the stress-sensitive Wistar Kyoto rat strain.
O' Mahony SM; Clarke G; McKernan DP; Bravo JA; Dinan TG; Cryan JF
Behav Brain Res; 2013 Sep; 253():310-7. PubMed ID: 23872358
[TBL] [Abstract][Full Text] [Related]
20. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation.
Agrawal A; Houghton LA; Morris J; Reilly B; Guyonnet D; Goupil Feuillerat N; Schlumberger A; Jakob S; Whorwell PJ
Aliment Pharmacol Ther; 2009 Jan; 29(1):104-14. PubMed ID: 18801055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
